IDDCR - Temple School Of Pharmacy (TUSP) Life Science - Clinical Research, Pharmacovigilance Programs To Help Industry Talent Crunch In India

International Drug Discovery and Clinical Research (IDDCR) and the prestigious Temple University's School of Pharmacy (TUSP) have joined hands in the delivery of global certificate programs to India. Starting in late August, IDDCR will bring Temple University's globally recognized Quality Assurance/Regulatory Affairs (QA/RA) graduate program to students in Hyderabad, offering one-year Post Graduate Diploma Programs that cover key concepts in the pharmaceutical industry.

IDDCR intends to educate 80 – 100 select students in Clinical Trial Management and Global Pharmacovigilance each year. The Certificate programs will help ease the demand for high-quality Clinical Trial and Pharmacovigilance professionals from Big Pharma, Start up, Generic Drug, Biotechnology, and Clinical Research organisations in India. The certificates consist of five concentrated courses and offer students the option of pursuing the Master's degree of Science at TUSP, USA.

Founded in 1884 in Philadelphia, PA, Temple University is the sixth largest provider of professional education in the U.S. and attracts more than 38,000 students to its 300 undergraduate and graduate programs each year. Established in 1968, its QA/RA graduate program is the oldest and most comprehensive of its type in the world. IDDCR provides practical training and resources for global biotech and pharmaceutical companies.

Vamsi Maddipatla, CEO of IDDCR announced: "We are excited to partner with Temple University in bringing their globally acknowledged certificate program in India, as our pharmaceutical industry in currently grappling with a talent crunch. Students in our Institute will be able to interface with Temple's experienced faculty in real time. Career opportunities also will be created for qualified graduates with local, national, and international biotech companies." Vamsi continued, "Various centers and institutions currently offer certification, but this initiative by IDDCR-Temple creates the only fully industry-focused certificate program in Clinical Trials and Pharmacovigilance in India."

Wendy Lebing, Assistant Dean at TUSP added, "We are excited to offer our courses in India with IDDCR, since India is becoming an important hub for the pharmaceutical industry and clinical research in the world. We eagerly look forward to this great relationship."

"The Indian CRO market is expected to grow (CAGR of ~30%) twice as fast as the global CRO industry over the next three years, creating a hug demand/supply gap of talented professionals. Our goal at IDDCR is to bridge this gap by combining industry-driven knowledge with practical orientation," Prashant Koirala, Corporate Development Head of IDDCR said. "We are committed to bringing together the best minds in industry and academia."

The One Year Certificate Program, open to graduate-level students, will commence at the IDDCR Institute in Hyderabad in late August 2011 through a series of real-time live lectures offered by the Temple University faculty by videoconferencing. Students will attend 36 hours (3 hours weekly) of class that include tests, assignments and a written examination. A local facilitator will attend each session to provide guidance and respond to questions.

Classes will be scheduled to accommodate working adults, including early mornings, weeknights, and weekends. Students will receive certificates issued by Temple University; upon completing a certificate, students can apply the course credits towards the master's degree in QA/RA, finishing their degree in the U.S. The application process will be facilitated by IDDCR.

Temple-IDDCR students will have the opportunity to work in Pharma and Biotech companies and gain practical experience while pursuing their studies. IDDCR welcomes industry firms to send their top talent to the certificate programs.

SOURCE: International Drug Discovery and Clinical Research (IDDCR)